Lumexa Imaging (NASDAQ:LMRI) Issues Earnings Results

Lumexa Imaging (NASDAQ:LMRI) released its earnings results on Thursday. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.71), Zacks reports. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $262.72 million.

Here are the key takeaways from Lumexa Imaging’s conference call:

• Q4 and full‑year results beat preliminary expectations — consolidated Q4 revenue was $267.7M (+7.9% YoY) and adjusted EBITDA was $63.8M (+18.6%) with a 23.8% margin; full‑year revenue was $1.023B and adjusted EBITDA $230.2M.
• Completed an IPO and used approximately $406M of net proceeds to pay down debt, reducing leverage to ~3.5x, securing upgraded ratings (S&P B+, Moody’s B2) and expected annual interest savings of more than $50M.
• Growth strategy remains focused on same‑center expansion and network growth — targeting 8–10 de novo openings per year (record nine opened in 2025), accelerating JV partnerships (e.g., UPMC) and disciplined tuck‑in M&A.
• Operational efficiency and tech adoption are driving throughput — AI‑enabled Fast Scan increased MRI schedule capacity by ~40% (50% fleet adoption end‑2025; ~two‑thirds expected by end‑2026) and a Ferrum Health partnership gives rapid access to FDA‑cleared AI apps.
• 2026 guidance reiterated (revenue $1.045B–$1.097B; adjusted EBITDA $234M–$242M; adjusted EPS $0.71–$0.77), but Q1 is expected roughly flat YoY due to some volume pull‑forward into Q4 and storm disruptions that the company expects to recover over the year.

Lumexa Imaging Stock Down 1.5%

NASDAQ LMRI traded down $0.12 during trading on Friday, hitting $7.65. 370,315 shares of the company’s stock traded hands, compared to its average volume of 797,599. Lumexa Imaging has a 12-month low of $7.23 and a 12-month high of $19.45. The business’s 50 day simple moving average is $13.53.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial raised Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 price objective for the company in a report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy” and a consensus price target of $23.00.

Hedge Funds Weigh In On Lumexa Imaging

Several hedge funds have recently made changes to their positions in LMRI. Readystate Asset Management LP purchased a new stake in shares of Lumexa Imaging in the 4th quarter valued at about $2,590,000. Ghisallo Capital Management LLC bought a new position in shares of Lumexa Imaging in the fourth quarter worth approximately $2,312,000. HBK Investments L P bought a new position in shares of Lumexa Imaging in the fourth quarter worth approximately $2,220,000. Squarepoint Ops LLC purchased a new stake in Lumexa Imaging in the fourth quarter valued at approximately $2,075,000. Finally, Geode Capital Management LLC bought a new stake in Lumexa Imaging during the fourth quarter valued at approximately $1,548,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).